Skip to main content
DrugPrice

Genotropin vs Norditropin

Side-by-side cost comparison based on Medicare Part D data

Norditropin costs 1% less per claim than Genotropin ($2,286.00 vs $2,303.00). A generic version of Norditropin is also available, which may reduce costs further.

Cost Per Claim

Genotropin$2,303.00
Norditropin$2,286.00

Medicare Spending

Genotropin$456.0M
Norditropin$567.0M

Beneficiaries

Genotropin22,000
Norditropin28,000

Annual Cost Per Patient

Genotropin$20,727.00
Norditropin$20,250.00

Full Comparison

MetricGenotropinNorditropin
Avg Cost Per Claim$2,303.00$2,286.00
Total Medicare Spending$456.0M$567.0M
Total Beneficiaries22,00028,000
Total Claims198,000248,000
Annual Cost/Patient$20,727.00$20,250.00
Year-over-Year Change-8.6%-4.2%
Generic AvailableYesYes
Patent ExpirationJan 31, 2023Jan 31, 2023
ManufacturerPfizerNovo Nordisk
ConditionGrowth DisordersGrowth Disorders
Generic NameSomatropinSomatropin

Genotropin vs Norditropin: What the Data Shows

Genotropin (Somatropin) and Norditropin (Somatropin) are both used to treat growth disorders. Based on Medicare Part D data, Norditropin costs $2,286.00 per claim, which is 1% less than Genotropin at $2,303.00 per claim.

Medicare spent $456.0M on Genotropin and $567.0M on Norditropin. In terms of patient reach, Norditropin serves more beneficiaries (28,000 vs 22,000).

Year-over-year spending changed -8.6% for Genotropin and -4.2% for Norditropin.

Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.

Frequently Asked Questions

Norditropin is cheaper at $2,286.00 per claim, compared to $2,303.00 for Genotropin. That makes Norditropin about 1% less expensive per claim based on Medicare Part D data.

Yes, both Genotropin and Norditropin are used to treat growth disorders. Your doctor can help determine which medication is more appropriate for your specific situation.

Both drugs have generic versions available. Generic Somatropin and generic Somatropin can offer significant cost savings — typically 80-95% less than the brand name.

Medicare Part D spent $456.0M on Genotropin covering 22,000 beneficiaries, and $567.0M on Norditropin covering 28,000 beneficiaries.

Explore Further

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.